Biobran

Effects of rice bran arabinoxylan compound on quality of life of cancer patients during active treatment: a randomised placebo-controlled pilot trial

demovic — Mon, 05 Oct 2026 10:11:55 +0000

The effects of a plant-based immunomodulator, rice bran arabinoxylan compound (RBAC), on the
quality of life (QoL) of cancer patients during active treatment are unclear. The RBAC-QoL study was
a randomised, placebo-controlled, double-blind feasibility study to address the role of RBAC in cancer
patients receiving systemic therapies. The primary outcome measure was patient-reported functional,
symptom, and global QoL scores. Secondary and exploratory outcome measures included nutritional
indices and cytokine changes. Adult patients (n = 29) with solid organ tumours (≥ stage II) undergoing
systemic treatment were recruited from outpatient centres in New South Wales, Australia. Group
allocation was assigned through stratified randomisation (RBAC = 12, placebo = 17). Interventions
were either RBAC or matched placebo at 3 g/day for 24 weeks. The participants, oncologists, and data
collectors were blinded. Data were collected from five study visits, 6 weeks apart. An intention-to-treat
analysis was performed using repeated measure ANOVA with pairwise comparisons where statistical
significance was observed. Data sets not conforming to normality were tested with nonparametric
ANOVA-type statistics. The global QoL scores differed significantly between groups with a large effect
size (p = 0.031, eta2[g] = 0.147). Pairwise comparisons found significant differences favouring the RBAC
group at week 6 (p = 0.017, Cohen’s d = 1.119) and week 24 (p = 0.041, d = 0.970). Compared to the
placebo group, the RBAC group showed significantly better role (p < 0.001) and social functioning (p
= 0.037), while the cognitive functioning score difference was trending higher (p = 0.055). Regarding
cancer symptoms, the placebo group reported significantly worse scores (p < 0.05) in fatigue, pain,
dyspnoea, and appetite loss compared to the RBAC group. Significant elevations (p < 0.05) of cytokine
interferon-γ, interleukin 1RA and 12p40, as well as total protein, were also detected in the RBAC group
compared to placebo over time. These serum markers correlated positively with the global QoL scores,
suggesting potential interactions of immune activity, nutritional status, and QoL. No intervention
related adverse events were reported in both groups. RBAC improves QoL beyond placebo during
systemic cancer treatment, potentially through the immuno-nutritional pathway.

Rice Bran Arabinoxylan Compound and Tryptophan Metabolism on Quality of Life of Cancer Patients: A Secondary Analysis of the RBAC QoL Study

demovic — Mon, 05 Oct 2026 09:58:36 +0000

Tryptophan metabolism, with its breakdown along the kynurenine pathway, is linked to the diminishing quality of
life (QoL) of cancer patients. Rice bran arabinoxylan compound (RBAC) is a plant-based immunomodulator shown
to improve the global QoL and functioning beyond the placebo during systemic cancer treatment in a randomised
controlled trial (RBAC-QoL study). However, whether RBAC improved QoL through the tryptophan pathway, and
the role of tryptophan and its kynurenine metabolite in these QoL outcomes, were not previously investigated. In this
study, serum tryptophan and kynurenine were analysed in samples collected from the RBAC-QoL study using a validated
liquid chromatography method with ultraviolet and fluorescence detection. This secondary analysis was conducted
using repeated-measures ANOVA, Spearman’s correlation, and linear mixed models. The results show that RBAC
supplementation had no statistically significant effect on tryptophan metabolism compared to the placebo. Tryptophan
significantly (P ⩽ .05) correlated positively with global QoL, physical and social functioning and negatively with fatigue,
dyspnoea, appetite loss and diarrhoea. Kynurenine also demonstrated significant (P ⩽ .05), but weaker correlations with
physical and social functioning (positively), as well as fatigue and dyspnoea (negatively), albeit weaker than tryptophan.
The kynurenine-to-tryptophan ratio exhibited no significant correlations with QoL. Stepwise reduction of a linear mixed
model of haematological, renal, liver, and immune markers revealed that tryptophan and gamma-glutamyl transferase
are prominent predictors of QoL (P < .001). RBAC and serum tryptophan appeared to have an additive effect on QoL.
Future research should investigate the combined impact of RBAC and tryptophan to assess any potential synergistic
effects.

Synchronizing activity of Biobran/MGN-3 with exosomes: Therapeutic targeting of hypoxia pathway to inhibit angiogenesis and proliferation of breast invasive ductal carcinoma

admin — Mon, 05 Oct 2026 09:04:16 +0000

Hypoxia-inducible factors (HIFs) are crucial for understanding and treating breast cancer, as low oxygen levels within tumors are key factors driving cancer progression, metastasis, and therapy resistance. We studied the possible role of exosomes in combination with Biobran/MGN-3, an arabinoxylan rice bran, in the HIF pathway via its pathogenesis and resistance to VEGF or Ang-2 inhibitors. Primary cultures of human breast cancer (BC) (invasive ductal carcinoma) and normal epithelial breast tissues were established. Primary BC cells were treated with the IC50 of Biobran and exosomes and exposed to moderate (5 % O2) and severe (0.02 % O2) hypoxic conditions. The mRNA expression of HIF-1a, VEGF, and Ang-2 and the protein levels of Bcl-2, p53, and caspase-3 were examined. Molecular docking in situ was also performed to predict and assess the affinity of Biobran for hypoxia-related targets: VHL, PHD, CBP, FIH, and VEGFR-2. Treatment with Biobran or its combination with exosomes attenuated the severe elevation of HIF-1a, VEGF, and Ang-2 levels and upregulation of both p53 and caspase-3 expression in tumor cells, while downregulating Bcl-2 expression. Molecular docking data revealed that PHD protein is the strongest binder to Biobran, with the strength of protein binding being PHD > VHL > CBP > VEGFR-2 > FIH. The present study demonstrates that both Biobran and exosomes enhance anti-tumor activity, suggesting the design of analogs for HIF-1a, VEGF, Ang-2, and Bcl-2 receptors for new anticancer therapies, offering potential for targeted cancer treatment.

Can a synergistic activation of pattern recognition receptors by plant immunomodulators enhance the effect of oncologic therapy? Case Report of a patient with uterus and ovary sarcoma. (Presented by Tibor Hajto, Lilla Baranyai, Angelika Kirsch, Monika Kuzma and Pal Perjési

admin — Fri, 21 Aug 2026 18:00:02 +0000

Breast Cancer Case Study 6 (Australia)

admin — Fri, 21 Aug 2026 17:56:44 +0000

Breast Cancer Case Study 7 (Australia)

admin — Fri, 21 Aug 2026 17:55:53 +0000

Prostate Cancer Case Study 2 (Australia)

admin — Fri, 21 Aug 2026 17:52:05 +0000

Prostate Cancer Case Study 3 (Australia)

admin — Fri, 21 Aug 2026 17:49:14 +0000

Can standardized and evidence based plant immunomodulator (rice bran arabinoxylan concentrate) increase the effect of Gemcitabine in a synergistic manner? Case report of a patient with ductal pancreas carcinoma (presented by Prof. Tibor Hajto)

admin — Fri, 21 Aug 2026 16:49:44 +0000

Basophilic Response in Patients with Persistent Symptoms Attributed to Lyme Borreliosis Treated with Hydrolysed Arabinoxylan Rice Bran

admin — Sat, 16 Aug 2025 20:11:00 +0000

Background and Objectives: MGN-3/Biobran (BRM4, Lentin Plus or Ribraxx) is a natural, rice bran-derived arabinoxylan immunoceutical that modulates the adaptive immune response to viral infections. In response to bacterial infections, basophils act as “first responders” and are also associated with modulation of the adaptive immune response. The maturation of pluripotent CD34+ stem cells into basophils is supported by the cytokine interleukin-3 (IL-3). The aim was to test the hypothesis that modulation of the adaptive immune response in bacterial infection by MGN-3/Biobran entails a basophilic response. The tick-related disorder Lyme borreliosis was chosen as the disease model; tick bites are associated with cutaneous IL-3-mediated basophil recruitment.

Materials and Methods: A three-month randomised double-blind placebo-controlled trial was conducted in patients with a history of borreliosis who were suffering from symptoms attributable to this disorder. The immunoceutical group received oral Biobran; the dosage for both groups was 1 g thrice daily. Both groups were matched for age, sex, and ethnicity. Results: A higher percentage of basophil count occurred in the immunoceutical group (p = 0.038). The final general linear model included the group (immunoceutical/placebo) and change in fatigue assessed by the 11-item Chalder Fatigue Questionnaire (CFQ) (r2 = 0.63; p = 0.0066). The change in basophil count was positively correlated with CFQ change (rs = 0.633; p = 0.020); only the immunoceutical group showed a positive correlation.

Conclusions: These results support the hypothesis being tested. Basophils may modulate the adaptive immune response by acting as immunoregulatory cells. They can regulate the functioning of type 2 T-helper lymphocytes, enhance immunological memory, and present antigens to CD8 T lymphocytes. Further studies are needed to clarify potential mechanistic factors and the timing of this basophilic response